10.12
İndüklenmiş Pluripotent Kök Hücreler
Kök hücreler, farklı hücre türlerini üreten farklılaşmamış hücrelerdir. Normalde, belirli bir hücre tipine farklılaşmış hücreler post-mitotiktir, yan…
- [Anlatıcı] Uyarılmış pluripotent kök hücreler, yani iPSC'ler, cilt hücreleri gibi farklılaşmamış embriyonik kök hücrelere benzer olmaları amacıyla laboratuar ortamında yeniden programlanan olgun ve farklılaşmış hücrelerdir. Yani, bölünürler ve pluripotentlerdir; vücutta herhangi bir hücre tipini üretebilirler. Örneğin zarar görmüş retin dokusunu onarmada kullanılan retina hücreleri.
İPSC'leri oluşturmak için, cilt fibroblastları gibi olgun hücreler, bir hastadan alınıp kültüre eklenir. Daha sonra, tipik olarak, transkripsiyon faktörleri için genler, viral vektörler tarafından, genomun içine dahil oldukları hücre çekirdeğine iletilir. Transkripsiyon faktörleri daha sonra embriyonik kök hücreler tarafından ifade edilen genlere döner ve onları etkin bir şekilde genel hale getirip pluripotent durumuna döndürürler.
Hücreler artık bölünebilir ve ideal olarak kültürde belirli bir hücre tipini üretmek üzere kullanılabilirler. Yeni hücreler daha sonra hasar veya hastalığı tedavi etmede en az ret ihtimaliyle hastaya geri verilirler çünkü bunlar aslında hastanın kendi hücreleridir.
View the full transcript and gain access to JoVE Core videos
Q1: What are induced pluripotent stem cells and how do they differ from other stem cells?
Induced pluripotent stem cells (iPSCs) are adult cells reprogrammed to an embryonic-like pluripotent state, capable of differentiating into any cell type. Unlike embryonic stem cells, iPSCs are generated from mature cells through genetic reprogramming, avoiding ethical concerns. This reprogramming involves activating master transcription regulators that reset gene expression patterns to enable unlimited self-renewal and differentiation potential.
Q2: How does gene expression control enable iPSC reprogramming?
iPSC reprogramming relies on precise gene expression control through transcription factors that activate pluripotency genes while silencing differentiation genes. Transcription regulators activators and repressors work together to rewrite the cellular epigenetic landscape. This coordinated regulation of expression occurs at multiple steps, from transcription initiation to translation, ensuring stable pluripotent identity and preventing spontaneous differentiation.
Q3: What role do transcription factors play in maintaining iPSC pluripotency?
Key transcription factors like Oct4, Sox2, and Nanog maintain iPSC pluripotency through combinatorial gene control synergistic action of transcription factors. These factors bind to regulatory DNA regions and recruit co-activators to activate pluripotency genes. Their cooperative binding of transcription regulators ensures robust, stable expression of genes required for self-renewal and prevention of differentiation.
Q4: How do eukaryotic transcription activators support iPSC function?
Eukaryotic transcription activators recruit co-activators and chromatin remodeling complexes to pluripotency gene promoters, facilitating RNA polymerase binding and transcription initiation. These activators recognize cis-regulatory sequences short fragments of non-coding DNA upstream of target genes. By assembling the pre-initiation complex at the eukaryotic promoter region, they enable robust expression of genes essential for iPSC maintenance.
Q5: What mechanisms prevent iPSCs from spontaneously differentiating?
iPSCs maintain pluripotency through active repression of differentiation genes via eukaryotic transcription inhibitors inhibiting DNA binding and blocking access to differentiation-promoting genes. Repressor proteins and silencing complexes bind regulatory regions to suppress lineage-specific gene expression. This dual mechanism of activating pluripotency genes while repressing differentiation genes creates a stable pluripotent state resistant to spontaneous differentiation.
Q6: How can iPSCs be directed to differentiate into specific cell types?
iPSC differentiation is controlled by removing pluripotency-maintaining signals and introducing lineage-specific transcription factors that activate cell-type-specific genes. This process involves coordinated changes in gene expression during transcription and translation stages. By manipulating transcriptional regulation through growth factors and signaling molecules, researchers can guide iPSCs toward desired cell fates for regenerative medicine applications.
Q7: What are the therapeutic applications of iPSC technology?
iPSCs enable generation of patient-specific cells for disease modeling, drug testing, and cell replacement therapies without immune rejection. Their ability to differentiate into any cell type makes them valuable for treating degenerative diseases, injuries, and genetic disorders. iPSC-derived cells bypass ethical concerns associated with embryonic stem cells while offering personalized regenerative medicine approaches for previously untreatable conditions.